cyc 202 has been researched along with daunorubicin in 3 studies
| Studies (cyc 202) | Trials (cyc 202) | Recent Studies (post-2010) (cyc 202) | Studies (daunorubicin) | Trials (daunorubicin) | Recent Studies (post-2010) (daunorubicin) |
|---|---|---|---|---|---|
| 979 | 7 | 393 | 8,239 | 886 | 1,310 |
| Protein | Taxonomy | cyc 202 (IC50) | daunorubicin (IC50) |
|---|---|---|---|
| 72 kDa type IV collagenase | Homo sapiens (human) | 1.9 | |
| Multidrug resistance-associated protein 1 | Homo sapiens (human) | 8 | |
| Histone deacetylase 1 | Homo sapiens (human) | 0.047 | |
| Histone deacetylase 8 | Homo sapiens (human) | 0.22 | |
| Histone deacetylase 6 | Homo sapiens (human) | 0.02 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Boddy, N; Burrows, F; Pallis, M; Russell, N; Seedhouse, C; Whittall, A | 1 |
| Ceckova, M; Cihalova, D; Hofman, J; Staud, F | 1 |
3 other study(ies) available for cyc 202 and daunorubicin
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Efficacy of RNA polymerase II inhibitors in targeting dormant leukaemia cells.
Topics: Acute Disease; Adenine Nucleotides; Antineoplastic Agents; Apoptosis; Arabinonucleosides; Azacitidine; Cell Line, Tumor; Cell Survival; Clofarabine; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Enzyme Inhibitors; Etoposide; Flavonoids; Heterocyclic Compounds, 4 or More Rings; Humans; Leukemia, Myeloid; Piperidines; Purines; RNA Polymerase II; RNA, Neoplasm; Roscovitine; Sirolimus; TOR Serine-Threonine Kinases | 2013 |
Purvalanol A, olomoucine II and roscovitine inhibit ABCB1 transporter and synergistically potentiate cytotoxic effects of daunorubicin in vitro.
Topics: Adenosine Triphosphatases; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; Cell Line; Cell Membrane; Cell Proliferation; Cyclin-Dependent Kinases; Daunorubicin; Drug Synergism; Gene Expression Regulation; Humans; Protein Kinase Inhibitors; Purines; RNA, Messenger; Roscovitine | 2013 |